Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

[11] Rondon G(2018)Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica 103 1317-1510

[12] Chen J(2019)Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT Bone Marrow Transplant 54 1499-1186

[13] Ciurea SO(2018)Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv 2 1180-1653

[14] Zhang MJ(2020)Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study J Hematol Oncol 13 27-224

[15] Bacigalupo AA(2020)Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL Front Oncol 10 320-1633

[16] Bashey A(2020)Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia Ann Hematol 99 1643-611

[17] Appelbaum FR(2021)Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT Bone Marrow Transplant 56 218-506

[18] Aljitawi OS(2009)Defining the intensity of conditioning regimens: working definitions Biol Blood Marrow Transplant 15 1628-1552

[19] Piemontese S(2016)Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission Bone Marrow Transplant 51 610-809

[20] Ciceri F(1999)Modeling random effects for censored data by a multivariate normal regression model Biometrics 55 497-1613

[11] Rondon G(2018)Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica 103 1317-1510

[12] Chen J(2019)Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT Bone Marrow Transplant 54 1499-1186

[13] Ciurea SO(2018)Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv 2 1180-1653

[14] Zhang MJ(2020)Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study J Hematol Oncol 13 27-224

[15] Bacigalupo AA(2020)Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL Front Oncol 10 320-1633

[16] Bashey A(2020)Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia Ann Hematol 99 1643-611

[17] Appelbaum FR(2021)Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT Bone Marrow Transplant 56 218-506

[18] Aljitawi OS(2009)Defining the intensity of conditioning regimens: working definitions Biol Blood Marrow Transplant 15 1628-1552

[19] Piemontese S(2016)Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission Bone Marrow Transplant 51 610-809

[20] Ciceri F(1999)Modeling random effects for censored data by a multivariate normal regression model Biometrics 55 497-1613